ArticleBMC pediatrics2026
Inflammatory biomarkers and symptom presence in pediatric corrosive substance ingestion: a retrospective study.
Article in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCorrosive substance ingestion is a significant clinical problem in the pediatric population, with challenges in early assessment due to the inconsistent relationship between symptoms and the severity of esophageal injury. Easily accessible inflammatory biomarkers have been proposed as adjunctive tools for early clinical evaluation. This study aimed to evaluate the association between inflammatory biomarkers and symptom presence in pediatric patients with corrosive substance ingestion and to assess their discriminative performance.
methodsThis retrospective study included 213 pediatric patients (aged 0-18 years) with corrosive substance ingestion. Patients were classified according to the type of ingested substance and the presence of symptoms. Inflammatory biomarkers including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII), systemic inflammatory response index (SIRI), and pan-immune-inflammation value (PIV) were calculated, and their association with symptom presence was analyzed.
resultsThe proportion of symptomatic patients was 8.5% (n = 18), with vomiting and hypersalivation being the most common symptoms. Neutrophil levels were higher (P = 0.016) and lymphocyte levels were lower (P = 0.007) in symptomatic patients, resulting in significantly elevated NLR (P = 0.002). PLR (P = 0.006), SII (P = 0.004), SIRI (P = 0.020), and PIV (P = 0.019) were also higher. NLR showed the best discriminative performance (AUC = 0.723; 95% CI: 0.557-0.888), with 61.1% sensitivity and 90.3% specificity at a cut-off of 2.15. Logistic regression confirmed a significant association between elevated NLR and symptom presence.
conclusionsInflammatory biomarkers, particularly NLR, were associated with symptom presence; however, their diagnostic or prognostic value is limited. They should not replace endoscopic evaluation. Further prospective studies are needed to validate their clinical utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.